DAVID SEPULVEDA: Open Payments
NPI 1316100381 · GONZALES, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,197 in 73 payments from 22 companies in 2025. Trend: 2023 $1,166 · 2024 $1,264 · 2025 $1,197
Food & beverage: $1,197
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 28 | $292 |
| GlaxoSmithKline, LLC. | 9 | $164 |
| Lilly USA, LLC | 5 | $85 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $79 |
| Novo Nordisk Inc | 4 | $65 |
| Antares Pharma, Inc. | 1 | $64 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $56 |
| Abbott Laboratories | 2 | $50 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $44 |
| Exact Sciences Corporation | 2 | $41 |
Products named: UBRELVY, TRELEGY ELLIPTA, VRAYLAR, QULIPTA, Kerendia, JARDIANCE, XYOSTED, TRINTELLIX.
Industry payments across LA — which companies pay providers there.
